Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New ultrasound technique could reveal hidden cancer spread in pancreatic patients

NCT ID NCT04899739

Diagnosis Sponsor: IHU Strasbourg Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a special ultrasound done before surgery can find small cancer spots that have spread from the main pancreatic tumor. Doctors used an endoscopic ultrasound to check lymph nodes near and far from the tumor. The goal was to see if this method could improve how doctors stage the cancer and decide on the best treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
endoscopic ultrasound (diagnostic test)
What this could lead to
If successful, this could help doctors more accurately stage pancreatic cancer before surgery, potentially avoiding unnecessary operations.
What could go wrong
This is a small, completed study with only 33 participants, so results may not apply to all patients. The test may not catch all hidden metastases.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

33 people

The number who actually took part.

Started

Dec 2021

Finished

Nov 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 95 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patient over 18 years old 2. Patient with a solid or degenerated cystic tumor of the pancreas requiring curative surgery 3. Patient with a complete clinical examination performed 4. Patient with no contraindication to anesthesia, upper digestive endoscopy and pancreatic surgery 5. Patient able to receive and understand information relating to the study and give informed written consent 6. Patient affiliated to the French social security system Exclusion Criteria: 1. Patient presenting with bleeding disease with disorder hemostasis and coagulation (PT \<60%, TCA\> 40 s and platelets \<60,000 / mm3) 2. Patient on anticoagulant or antiaggregant treatment that cannot be temporarily interrupted 3. Patient carrying a right-left shunt, a severe pulmonary arterial hypertension (high blood pressure pulmonary\> 90 mm Hg), uncontrolled systemic hypertension or suffering from respiratory distress syndrome. 4. Pregnant or breastfeeding patient 5. Patient in exclusion period (determined by a previous study or in progress) 6. Patient under legal protection 7. Patient under guardianship or trusteeship

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pancreatic cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pancreatic cancer

Contacts and locations

Locations

  • Service de Chirurgie Digestive et Endocrinienne

    Strasbourg, 67000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.